If you have any questions for next week's webinar guest speakers (Clifford Gross Ph.D, CEO, Tekcapital, Mark Selby, Chair & CEO, Canada Nickel, Robin Brundle, Chairman, Technology Minerals and Werner Klingenberg, CEO, Goldplat) please submit here.
Captain, what are you not getting? The more the company keep the lid on the dispute details within the piblic domain the less likely a competitor approaches or even attempts a hostile takeover due to the uncertainty. The fact they have now raised a claim for £134m enforced this point further.
Also, they do want to bring in II’s and judging by the comprehensiveness of the presentation i cannot see why some risk averse funds dont take a starter position here at £110 mcap. Potentially, some sharks like BIO may be onnthe prowl aswel. The strengths of this business have always been thr R&D and judging by the development of the covid assays i would bet they develop some really good non-covid ones. Also a key nugget was the M&A could actually increase the timescales for achieving £100m and infact exceed that target.
Overall, think they delivered it well. Hillseekers post sums up really well the position the company finds themselves in currently transtioning from covid to non covid.
The main take away for me is the continuous signalling of utilising the capital for growth using three key areas including M&A. Very significant news given the claim by DHSC. Additionally, James’ response to the dispute question was reassuring saying they see this as progresion essentially. It could be they expected it as dealy tactic but eventually we will get there.
RE: rns already out on Zone bourse28 Apr 2022 08:45
Rns wasnt that bad. The restated revenue guidance has caused the drop but looking beyond that Q4 this year and first halfnnext year could be interesting especially with a favourable dispute resolution. There is vakue in buying at these levels imo and i think funds and Bio will see it that way.
RE: rns already out on Zone bourse28 Apr 2022 07:42
Current year guidance coming in lower than expected in January which is a bit of a bummer but the decline in testing is likely to continue fornthe remainder of the year.
However, more importantly now we have a strategy to innovate and inorganically grow the company to deliver in EXCESS of £100m revenues in 5 years whilst mainting industry standard margins. Industry standard EBITDA sees us at around £35-£40m at a multiple of 20 for the sector values us at £700m. Current MCAP £116m. Value is there to invest. Hopefully some more PDMR’s, maybe BIO increasing and some funds join us.
Lets hear what he has to say at 12 and what the market makes of this!
Wbafc, the last time we had a rns confirming a product was added to the ctda list we actually finished red! The market is not interested in anything covid related any longer. We need a strategy for future growth.
Interesting considering it will cost c.£30m ball park. They must have done well, looking across the sector i see a theme so if we havent pushed december sales into jan i will be surprised given our year end revenue.
RE: cash in bank increasing daily24 Mar 2022 13:02
The revenue forecast was extremely pessimistic and maybe stated to allow Bio to buy in on the cheap. (If they are agreeing a merger) my guess is revenue has been good this far hence the director and PA buys. With the audit office agreeing the dhsc awarded dodgy contracts i hope and following DA’s own words our end of the contract was tight snd we have very strong grounds to assert the obligation to pay. If all this comes through by year end an optimistic cash position could well be £200m +
RE: Dispute resolution and Takeover14 Mar 2022 13:20
If the dispute is reolved and we get paid in full. We could have £3 SP in cash by year end. I will not be accepting that as a PI! However, i imagine if that is the case the SP will be well in excess of £3 before then
I wouldnt be surprised. If nova are not in with Bio purchasing they could get potentially get a ‘white knight’ to buy shares to increase the price as a defensive play. Seen it happen before and Nova are in cahoots with Tata a group worth £230 billion!
Soumya Swaminathan, the chief scientist at the World Health Organization, tweeted on Tuesday: “We have known that recombinant events can occur, in humans or animals, with multiple circulating variants of #SARSCoV2. “Need to wait for experiments to determine the properties of this virus. Importance of sequencing, analytics & rapid data sharing as we deal with this pandemic.”